Long-acting GLP-1 analogs (mimetics) and highly selective inhibitors of the incretin-degrading enzyme, dipeptidyl peptidase-4 (DPP-IV), are now widely used as T2DM therapeutics. Here, DPP4 is linked to type 2 diabetes mellitus.